Loading...
Loading...
Synergy Pharmaceuticals, Inc.
SGYP, a developer of new drugs to treat gastrointestinal (GI)
disorders and diseases, announced today that an Investigational New Drug (IND)
application was submitted on September 7, 2012 for clinical evaluation of
SP-333 to treat inflammatory bowel disease (IBD). SP-333 is a
second-generation guanylate cyclase-C (GC-C) agonist with the potential to
treat GI disorders and diseases.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in